KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$55959.0.

  • Co-Diagnostics' Gains from Investment Securities fell 11909.43% to -$55959.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $740621.0, marking a year-over-year decrease of 3179.95%. This contributed to the annual value of $1.0 million for FY2024, which is 0.0% changed from last year.
  • Per Co-Diagnostics' latest filing, its Gains from Investment Securities stood at -$55959.0 for Q3 2025, which was down 11909.43% from $970570.0 recorded in Q2 2025.
  • Over the past 5 years, Co-Diagnostics' Gains from Investment Securities peaked at $1.1 million during Q2 2021, and registered a low of -$464943.0 during Q1 2021.
  • Its 5-year average for Gains from Investment Securities is $465119.4, with a median of $425446.0 in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 12191.25% in 2021, then surged by 546787.85% in 2023.
  • Co-Diagnostics' Gains from Investment Securities (Quarter) stood at $670569.0 in 2021, then crashed by 99.63% to $2503.0 in 2022, then soared by 5467.88% to $139364.0 in 2023, then soared by 97.64% to $275443.0 in 2024, then tumbled by 120.32% to -$55959.0 in 2025.
  • Its last three reported values are -$55959.0 in Q3 2025, $970570.0 for Q2 2025, and $970570.0 during Q1 2025.